GlassScriptPhysician profile
Patrick J Colarusso
NPI 1144238825
$5,128.58
in general payments reported to CMS, 2019-2025
25 companies · $978 in 2025
The $978 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $735 · 2021: $1,147 · 2022: $611 · 2023: $422 · 2024: $579 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.07 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $652.52 | 2019-2025 | Erleada |
| Incyte Corporation | $631.96 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $624.92 | 2019-2025 | |
| Seagen INC. | $487.75 | 2019-2023 | Padcev, Tukysa |
| Alexion Pharmaceuticals, INC. | $344.61 | 2019-2022 | |
| Pfizer INC. | $294.58 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.49 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $232.56 | 2021 | |
| Merck Sharp & Dohme LLC | $207.75 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $194.95 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $145.65 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $143.19 | 2020-2025 | |
| Beigene USA, INC. | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $124.00 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $116.71 | 2021 | |
| Lilly USA, LLC | $99.20 | 2020 | |
| Sumitomo Pharma America, INC. | $60.71 | 2024-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $25.92 | 2025 | |
| Tempus Ai, INC | $25.34 | 2024 | |
| Endo USA, INC. | $23.06 | 2025 | Xiaflex |
| Eisai INC. | $12.99 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Colarusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.